JAK2 and myeloproliferative disorder: At this point in time, pegylated interferon is the most important MPN therapy because of its selective MPN HSC targeting and survival effects, but when and how best to use it alone or in combination with a nonspecific JAK2 inhibitor are still unclear for these chronic diseases with long survival.